Status:

WITHDRAWN

Clinical Outcomes of Patients Implanted With the RxSight Light Adjustable Lens (LAL)

Lead Sponsor:

Vance Thompson Vision

Conditions:

Cataract

Pseudophakia

Eligibility:

All Genders

40-80 years

Brief Summary

The objective of this investigator initiated study (IIT-002) is to collect data on commercial patients implanted with the RxSight Light Adjustable Lens (LAL).

Eligibility Criteria

Inclusion

  • Sign a written Informed Consent Document
  • Implanted commercially with the LAL and completed LDD light treatments

Exclusion

  • Previous corneal or intraocular surgery other than removal of cataract and implantation of the LAL

Key Trial Info

Start Date :

August 13 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06488066

Start Date

August 13 2021

End Date

January 1 2022

Last Update

July 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vance Thompson Vision

Sioux Falls, South Dakota, United States, 57108